Q702 for the Treatment of Patients With Hematologic Malignancies
Plain-language summary
This Phase 1 trial is evaluating Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, and other medications as a treatment for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Axl/Mer/CSF1R Inhibitor Q702 (DRUG): Given PO | Biospecimen Collection (PROCEDURE): Undergo blood and urine sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow biopsy and aspiration | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy and aspiration | Computed Tomography (PROCEDURE): Undergo CT scan | Magnetic Resonance Imaging (PROCEDURE): Undergo MRI | Positron Emission Tomography (PROCEDURE): Undergo PET scan | Survey Administration (OTHER): Ancillary study
- Drugs / treatments
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details